LOWPLAT PLUS TAB
LOWPLAT PLUS TAB (Clopidogrel 75mg+Aspirin 75mg )
- Lowers Frequency of MI with Long-Term DAPT.
- Recommended After TIA or Minor Stroke
Clopidogrel is a prodrug, one of whose metabolites is an inhibitor of platelet aggregation.
Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that
inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the
binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent
ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet
aggregation. This action is irreversible. Consequently, platelets exposed to clopidogrel’s
active metabolite are affected for the remainder of their lifespan (about 7 to 10 days). Platelet
aggregation induced by agonists other than ADP is also inhibited by blocking the
amplification of platelet activation by released ADP.
Because the active metabolite is formed by CYP450 enzymes, some of which are
polymorphic or subject to inhibition by other drugs, not all patients will have adequate platelet
inhibition.
Aspirin inhibits prostaglandin synthesis resulting in inhibition of platelet aggregation for their
lifespan of about 7-10 days. The acetyl group of aspirin binds with a serine residue of
cyclooxygenase-1 (COX-1), resulting in irreversible inactivation of the enzyme. Inhibition of
COX-1 prevents conversion of arachidonic acid to thromboxane A2 (TXA2), which is a
potent agonist of platelet aggregation.
